Clovis: Rucaparib recommended for United Kingdom women with relapsed ovarian cancer

Clovis: Rucaparib recommended for United Kingdom women with relapsed ovarian cancer

BOULDER -- Clovis Oncology, Inc . (NASDAQ: CLVS) announced the National Institute for Health and Care Excellence (NICE) has recommended that women with relapsed ovarian cancer in England have... Read More

Monday October 14, 2019 0 comments Tags: Boulder, Clovis Oncology, Rucaparib, Patrick J. Mahaffey

Clovis updates data on Rubraca clinical trial

Clovis updates data on Rubraca clinical trial

BOULDER -- Clovis Oncology, Inc. (NASDAQ: CLVS) announced updated data from the Phase 2 TRITON2 trial at the European Society for Medical Oncology (ESMO) Congress 2019, reinforcing the... Read More

Monday September 30, 2019 0 comments Tags: Boulder, Clovis Oncology, Rubraca, Patrick J. Mahaffy

Clovis to collaborate with German biotech company

Clovis to collaborate with German biotech company

BOULDER/BERLIN -- Clovis Oncology, Inc. (NASDAQ: CLVS) announced it has entered into a global licensing and collaboration agreement with 3B Pharmaceuticals GmbH (3BP), a private German... Read More

Tuesday September 24, 2019 0 comments Tags: Boulder, Clovis Oncology, 3B Pharmaceuticals, Patrick Mahaffy

Clovis Oncology to offer $225M in convertible senior notes to investors

Clovis Oncology to offer $225M in convertible senior notes to investors

BOULDER -- Clovis Oncology, Inc . (NASDAQ: CLVS) announced it intends to offer $225 million aggregate principal amount of its convertible senior notes due 2024 in a private placement to... Read More

Thursday August 8, 2019 0 comments Tags: Boulder, Clovis Oncology

Clovis Oncology names Ginger Graham board chair

Clovis Oncology names Ginger Graham board chair

BOULDER -- Clovis Oncology, Inc . (NASDAQ: CLVS) announced the appointment of Ginger L. Graham as chair of the companys board of directors following the retirement of former board chair Dr. ... Read More

Friday June 7, 2019 0 comments Tags: Boulder, Clovis Oncology, Ginger Graham, Patrick J. Mahaffy

Clovis Oncology to receive $175M to fund company’s largest clinical trial

Clovis Oncology to receive $175M to fund company’s largest clinical trial

BOULDER -- Clovis Oncology, Inc . (NASDAQ: CLVS) today announced it has entered into an agreement for up to $175 million in non-dilutive clinical trial financing with certain affiliates of TPG... Read More

Thursday May 2, 2019 0 comments Tags: Boulder, Clovis Oncology, Patrick J. Mahaffy, TPG Sixth Street Partners, ATHENA study, Rubraca

Clovis Oncology announces interim results for drug treating pancreatic cancer

Clovis Oncology announces interim results for drug treating pancreatic cancer

BOULDER -- Clovis Oncology, Inc. (NASDAQ: CLVS) today announced interim results from an investigator-initiated Phase 2 trial of Rubraca (rucaparib) in platinum-sensitive patients with advanced... Read More

Tuesday April 2, 2019 0 comments Tags: Boulder, Clovis Oncology, Patrick J. Mahaffy, Rubraca

Clovis Oncology: Rubraca now available in Germany for ovarian cancer therapy

Clovis Oncology: Rubraca now available in Germany for ovarian cancer therapy

BOULDER MUNICH -- Clovis Oncology, Inc . (NASDAQ: CLVS) announced Rubraca (rucaparib) is now available by prescription in Germany as monotherapy for the maintenance treatment of adults with... Read More

Tuesday March 5, 2019 0 comments Tags: Boulder, Clovis Oncology, Rubraca, Patrick J. Mahaffy